Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has provided an update.
Lumos Diagnostics has signed a second distribution agreement for its FebriDx® test in Australia and New Zealand with Amtech, part of YesGroup. This partnership, alongside an existing agreement with Henry Schein, aims to expand the accessibility of FebriDx®, a rapid test that differentiates between bacterial and viral infections, thereby supporting informed clinical decisions and reducing unnecessary antibiotic use.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid point-of-care diagnostic test technology, offering customized assay development, manufacturing services, and proprietary digital reader platforms. The company focuses on developing, manufacturing, and commercializing point-of-care tests targeting infectious and inflammatory diseases.
Average Trading Volume: 6,745,638
Technical Sentiment Signal: Buy
Current Market Cap: A$98.89M
Learn more about LDX stock on TipRanks’ Stock Analysis page.